ReachRxResearch
Home
Research
Sign Up
Executive Summary of the 2025 World Allergy Organization Guidelines for Hereditary Angioedema
Back to Research Hub
  1. Home
  2. Research Hub
  3. Executive Summary of the 2025 World Alle…

Executive Summary of the 2025 World Allergy Organization Guidelines for Hereditary Angioedema

World Allergy Organization Journal·October 27Open Access
AllergyPractice changingHereditary AngioedemaClinical Practice GuidelineAntifibrinolyticAttenuated AndrogenBradykinin Receptor AntagonistC1 Inhibitor ConcentrateFactor XIIa InhibitorPlasma Kallikrein InhibitorMixedTakhzyroBerotralstatDonidalorsenEcallantideGaradacimabIcatibantLanadelumabSebetralstatTranexamic Acid

Summary

View source

What was studied

This executive summary of the 2025 WAO Guidelines covers the classification, diagnosis, and management of hereditary angioedema (HAE), including an updated endotype-based framework distinguishing bradykinin-mediated, VEGF-mediated, mast cell-mediated, and idiopathic forms, with guidance on on-demand treatment, short-term prophylaxis, and long-term prophylaxis.

Key findings

First-line on-demand treatments are C1-INH concentrate (IV), icatibant (SC), and sebetralstat (oral); first-line long-term prophylaxis options include plasma-derived C1-INH (SC), lanadelumab (SC), berotralstat (oral), garadacimab (SC), and donidalorsen (SC), selected via a treat-to-target approach aimed at freedom from attacks and quality-of-life impairment.

Study limitations

This is an executive summary of a guideline — not a primary study — so it does not report original trial data, effect sizes, or patient-level outcomes. Global disparities in access to diagnostics and therapies limit universal applicability of the recommendations.

Clinical implications

Suspect HAE in any patient with recurrent angioedema without urticaria, especially with abdominal or airway involvement, early onset, or family history; confirm with C1-INH functional testing. Ensure all HAE patients have access to at least 2 doses of effective on-demand therapy, and individualize long-term prophylaxis using a treat-to-target strategy with regular reassessment.

Caveats

  • Guideline recommendations, strength of evidence, and specific drug endorsements cannot be extracted without access to the full text
  • No full text was provided for this paper; all summary fields are null due to insufficient source content
  • Several therapies listed (e.g., garadacimab, donidalorsen, sebetralstat) have variable regulatory approval across countries; local availability must be verified before prescribing
Show all 5
  • The endotype-based classification framework is explicitly described as dynamic and subject to revision as new genetic and molecular evidence emerges
  • This is an executive summary, not the full guideline; complete evidence grading, methodology, and all recommendations are only available in the primary guideline document

Related Questions

Explore related topics

Current guidelines for hereditary angioedema management and prophylaxisWAO 2025 guidelines hereditary angioedema managementWhat are the latest options for long-term prophylaxis in hereditary angioedema with C1 inhibitor deficiency?On-demand vs long-term prophylaxis treatment options for hereditary angioedemahereditary angioedema acute treatment and prophylaxis recommendationsHow do I differentiate bradykinin-mediated angioedema from histamine-mediated angioedema in clinical practice?C1 inhibitor deficiency bradykinin-mediated angioedema therapyWhat is the role of genetic testing in diagnosing hereditary angioedema with normal C1 inhibitor?Bradykinin pathway therapies for hereditary angioedema: kallikrein inhibitors and C1 esterase inhibitors

Publication Details

Year
2026
Journal
World Allergy Organization Journal
Source
View article
Keep scrolling
More content below.
Up Next